Coherus declares special CVR dividend for legacy biosimilar asset proceeds

Coherus Oncology, Inc.

One CVR per share of common stock; record date Sept 30, 2026, distribution Oct 7, 2026.
CVRs entitle holders to net cash proceeds from sale/licensing of Legacy BioSim Assets (patents, IP, royalties, cell lines).
CVRs non-transferable, no trading market, expire Oct 7, 2028; no guaranteed payment.
Company retained investment bank as capital markets advisor for sale process; Loan Agreement with Innovatus Life Sciences restricts dispositions.
CVRs not certificated, no voting rights, no interest; tax treatment uncertain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.